Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bollito, E.
Right arrow Articles by Dogliotti, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bollito, E.
Right arrow Articles by Dogliotti, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:S159-S164, 2001
© 2001 European Society for Medical Oncology

Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma

E. Bollito1, A. Berruti2, M. Bellina3, A. Mosca2, E. Leonardo1, R. Tarabuzzi3, S. Cappia1, M. Mari3, M. Tampellini2, D. Fontana3, L. Gubetta1, A. Angeli2 and L. Dogliotti2

1 Dipartimento di Anatomia Patologica, Dipartimento di Scienze Cliniche e Biologiche, Universuà di Torino Orbassano, Italy
2 Oncologia Medica, Medicina Interna Orbassano, Italy
3 Urologia, Azienda Ospedaliera San Luigi Orbassano, Italy

Correspondence to: Correspondence to E. Bollito, MD Anatomia Patologica Azienda Ospedaliera San Luigi Regione Gonzole 10 10043 Orbassano, Italy E-mail. Luigi.Dogliotti{at}Unito.it

Purpose: The biological behaviour of prostate cancer is highly variable and prediction by the commonly employed prognostic parameters is not sufficient. The concept of neuroendocrine (NE) differentiation in prostate adenocarcinoma has recently received increasing attention due to possible implications for prognosis and therapy.

Materials and Methods: Core needle biopsies from 142 newly diagnosed patients were immunohistochemically examined for the coexistence of NE differentiation using an antibody against chromogranin A (CgA). Circulating CgA was available in 106 of these patients.

Results: NE differentiation was found in 64(45.1%) tumors. Among them 29 (20.4%) had CgA positive cells scattered or focally distributed in less than 5% per mm of tumor tissues, 26 (18.3%) between 5% and 10% and 9 (6.4%) more than 10%, respectively. There was a significant correlation between the extent of NE features and either Gleason score (P < 0.01) or stage of disease. Circulating CgA but not PSA correlated with immunohistochemical CgA (P < 0.03) particularly in metastatic cases.

Conclusions: These data support the concept that NE differentiation in human prostate cancer has a negative prognostic significance. Circulating CgA levels reflect immunohistochemical findings.

chromogranin A, neuroendocrine differentiation, prostate carcinoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
A Berruti, A Mosca, M Tucci, C Terrone, M Torta, R Tarabuzzi, L Russo, C Cracco, E Bollito, R M Scarpa, et al.
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease
Endocr. Relat. Cancer, March 1, 2005; 12(1): 109 - 117.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.